Publisher details
Available items(s) from this publisher (1310)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Surveillance de la sécurité vaccinale en Belgique / Jo Robays / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
Surveillance de la sécurité vaccinale en Belgique : place et limites d'une approche reposant sur les taux de base [printed text] / Jo Robays, Author ; Germaine Hanquet, Author ; Dominique Roberfroid , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2012 . - VII, 114 p. : Ill. ; A4. - (KCE Reports B. Health Services Research (HSR); 188B) .
ISSN : D/2012/10.273/70 : € 0,00
Languages : English (eng) French (fre)
Descriptors: Indexation
2011-22 ; Adverse Drug Reaction Reporting Systems ; Pharmacovigilance ; Product Surveillance, Postmarketing ; R188 ; Vaccination
Classification
QW 805 Vaccines. Antitoxins. ToxoidsContents note: 1 INTRODUCTION 11 -- 1.1 DIFFÉRENTES APPROCHES DE DÉTECTION DES SIGNAUX 12 -- 1.2 OBJECTIF DE L'ÉTUDE. 12 -- 2 BASE DE DONNÉE PERMETTANT DE FOURNIR LE TAUX DE BASE EN BELGIQUE. 13 -- 2.1 SOURCES DE DONNÉES ADMINISTRATIVES 13 -- 2.1.1 Le résumé clinique minimum (RCM) 13 -- 2.1.2 CARENET 13 -- 2.1.3 Registre des décès 14 -- 2.2 RÉSEAUX SENTINELLES 14 -- 2.2.1 Réseaux de MG 14 -- 2.2.2 Pedisurv 15 -- 3 ESTIMATION DES TAUX DE BASE : UNE ÉTUDE PILOTE 15 -- 3.1 MORT SUBITE DU NOURRISSON 15 -- 3.2 SYNDROME DE GUILLAIN-BARRÉ 16 -- 3.3 EPILEPSIE 17 -- 3.4 FAISABILITÉ ET FIABILITÉ DU CALCUL DES TAUX DE BASE EN BELGIQUE 17 -- 4 DÉFIS ET OPPORTUNITÉS DE LA SURVEILLANCE DE LA SÉCURITÉ VACCINALE 18 -- 4.1 SURVEILLANCE DE LA SÉCURITÉ VACCINALE EN BELGIQUE 18 -- 4.1.1 Collecte des données 18 -- 4.1.2 Analyse des données 20 -- 4.2 LIMITATIONS ET PISTES DE SOLUTION 20 -- 5 UN PAS EN AVANT?. 23 -- SCIENTIFIC REPORT 24 -- 1 BACKGROUND OF THE STUDY 24 -- 2 BACKGROUND RATES IN SAFETY SURVEILLANCE: OVERVIEW OF ISSUES 26 -- 2.1 USING BACKGROUND RATES FOR SIGNAL DETECTION. 26 -- 2.1.1 Computation 26 -- 2.1.2 Signal management: prioritization and evaluation 27 -- 2.2 CHALLENGES AND OPTIONS IN PHARMACOVIGILANCE BASED ON BACKGROUND RATES 28 -- 2.2.1 Counting events 28 -- 2.2.2 Counting exposed ones 31 -- 2.2.3 Confounding 32 -- 2.2.4 Analytical issues 33 -- 2.3 CHALLENGES AND OPPORTUNITIES FOR VACCINE SAFETY SURVEILLANCE BASED ON A -- BACKGROUND APPROACH 34 -- 3 BELGIAN DATABASES FOR COMPUTING BACKGROUND RATES 37 -- 3.1 INTRODUCTION & METHODS 37 -- 3.2 DESCRIPTION OF THE DATABASES 37 -- 3.2.1 Minimal Clinical Data 37 -- 3.2.2 Carenet 38 -- 3.2.3 GP sentinel practice networks 38 -- 3.2.4 Special Solidarity Fund 39 -- 3.2.5 Increased child allowance for disabled or ill children 39 -- 3.2.6 Pedisurv 39 -- 3.2.7 Cause-specific deaths 40 -- 3.2.8 The European Mortality Monitoring Project 40 -- 3.2.9 Vaccinnet 41 -- 3.2.10 Disease reporting at regional level 41 -- 3.3 CONCLUSION 42 -- 4 BACKGROUND RATES IN EUROPE 42 -- 4.1 GENERAL INTRODUCTION 42 -- 4.2 METHODS 42 -- 4.3 POPULATION 43 -- 4.4 OUTCOMES 43 -- 5 ESTIMATION OF BACKGROUND RATES FOR SELECTED CONDITIONS IN BELGIUM 45 -- 5.1 SUDDEN INFANT DEATH 45 -- 5.1.1 Definitions 45 -- 5.1.2 Literature review 46 -- 5.1.3 Rates of SID in Belgium 50 -- 5.1.4 Conclusions on sudden infant deaths 53 -- 5.2 SUDDEN DEATH WITH UNKNOWN CAUSE IN ≥1 YEAR OF AGE 53 -- 5.2.1 Rationale 53 -- 5.2.2 Definitions 53 -- 5.2.3 Literature review 55 -- 5.2.4 Rates of sudden deaths in Belgium 56 -- 5.2.5 Conclusions on sudden deaths 60 -- 5.3 GUILLAIN-BARRÉ SYNDROME 60 -- 5.3.1 Rationale 60 -- 5.3.2 Definitions 60 -- 5.3.3 Literature review 60 -- 5.3.4 Background rates of Guillain-Barré Syndrome in the literature 61 -- 5.3.5 Seasonal or temporal patterns 63 -- 5.3.6 Prediction models 63 -- 5.3.7 Belgian data on GBS from Minimal Clinical Data 63 -- 5.3.8 Conclusions on Guillain-Barré syndrome (GBS) 65 -- 5.4 SEIZURES 66 -- 5.4.1 Case definition 66 -- 5.4.2 Literature review 66 -- 5.4.3 Results 67 -- 5.4.4 Belgian data 69 -- 5.4.5 Discussion 69 -- 6 POTENTIAL DETECTION OF CASES OF SD/SID, GBS, THROMBOCYTOPENIA AND -- CONVULSIONS FROM IMMUNOGLOBULIN’S PRESCRIPTIONS 69 -- 6.1 IMMUNOGLOBULINS FOR EXTRAVASCULAR ADMINISTRATION (J06BA01) 70 -- 6.2 IMMUNOGLOBULINS FOR INTRAVASCULAR ADMINISTRATION (J06BA02) 71 -- 7 MINIMAL CLINICAL DATA 72 -- 7.1 GUILLAIN-BARRÉ SYNDROME 72 -- 7.2 SEIZURES. 74 -- 7.3 DEMYELINATING DISEASE 75 -- 7.4 OPTIC NEURITIS 76 -- 7.5 BELL’S PALSY 77 -- 7.6 THROMBOCYTOPENIA 78 -- 7.7 GENERAL DISCUSSION ON MCD DATA 78 -- 8 PHARMACOVIGILANCE IN BELGIUM 79 -- 8.1 DATA COLLECTION 79 -- 8.2 DATA ANALYSIS 81 -- 9 GENERAL DISCUSSION AND RECOMMENDATIONS 82 -- APPENDICES. 83 -- REFERENCES 108 Link for e-copy: https://doi.org/10.57598/R188B Format of e-copy: PDF (1,17 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3087 Copies(0)
Status No copy Surveillance de la sécurité vaccinale en Belgique / Jo Robays / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
Surveillance de la sécurité vaccinale en Belgique : place et limites d'une approche reposant sur les taux de base - Synthèse [printed text] / Jo Robays, Author ; Germaine Hanquet, Author ; Dominique Roberfroid , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2012 . - 15 p. : Ill. ; A4. - (KCE Reports B. Health Services Research (HSR); 188BS) .
ISSN : D/2012/10.273/73 : € 0,00
Languages : French (fre)
Descriptors: Indexation
2011-22 ; Adverse Drug Reaction Reporting Systems ; Pharmacovigilance ; Product Surveillance, Postmarketing ; R188 ; Vaccination
Classification
QW 805 Vaccines. Antitoxins. ToxoidsLink for e-copy: https://doi.org/10.57598/R188BS Format of e-copy: PDF (321 KB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3088 Copies(0)
Status No copy Survival and Quality of care offered in Belgian hospitals with and without recognition for breast cancer / Roos Leroy / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2023)
Survival and Quality of care offered in Belgian hospitals with and without recognition for breast cancer [printed text] / Roos Leroy , Author ; Cindy De Gendt, Author ; Jolyce Bourgeois , Author ; Julie Verbeeck, Author ; Isabelle Savoye, Author ; Geert Silversmit, Author ; Nancy Van Damme, Author ; B. Carly, Author ; Cécile Colpaert, Author ; Pino Cusumano, Author ; Pieter De Visschere, Author ; Jan Decloedt, Author ; Joelle Desreurx, Author ; François Duhoux, Author ; Luigi Moretti, Author ; Mirela Roman, Author ; Donatienne Taylor, Author ; Liv Veldeman, Author ; Didier Verhoeven, Author ; Hans Wildiers, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2023 . - 428 p. : ill. ; A4. - (KCE Reports. Health Services Research (HSR); 365C) .
ISSN : D/2023/10.273/03 : € 0,00
Languages : English (eng)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
Breast Neoplasms ; Physician's Practice Patterns ; Quality Assurance, Health Care ; Quality Indicators, Health Care ; Quality of Health CareContents note: SCIENTIFIC REPORT 31 -- 1 INTRODUCTION .31 -- 1.1 THE BELGIAN SITUATION IN A NUTSHELL .31 -- 1.1.1 The European incentive to establish breast clinics .31 -- 1.1.2 The move to coordinating and satellite breast clinics – a further reduction in the minimal level of activity 32 -- 1.2 RESEARCH QUESTIONS .33 -- 1.3 SECONDARY OBJECTIVES 33 -- 1.4 TARGET AUDIENCE 34 -- 1.5 METHODOLOGY 34 -- 1.6 STRUCTURE OF THE REPORT 35 -- 2 BACKGROUND 36 -- 2.1 BREAST CANCER, THE MOST COMMONLY DIAGNOSED CANCER AMONG WOMEN 36 -- 2.2 BREAST CANCER CARE IN BELGIUM .39 -- 2.2.1 Screening for breast cancer 39 -- 2.2.2 Concentration of breast cancer care, only to some extent .39 -- 2.2.3 Gene expression profiling – agreements solely with coordinating and satellite breast clinics .45 -- 2.2.4 Autologous breast reconstruction – agreements solely with coordinating breast clinics .45 -- 2.3 QUALITY IMPROVEMENT INITIATIVES AT THE EUROPEAN LEVEL 45 -- 2.3.1 EUSOMA’s position papers on specialist breast units 45 -- 2.3.2 The European Commission Initiative on Breast Cancer 47 -- 3 IDENTIFICATION, SELECTION AND OPERATIONALIZATION OF PROCESS INDICATORS .49 -- 3.1 IDENTIFICATION AND SELECTION OF POSSIBLE QUALITY INDICATORS .49 -- 3.2 OPERATIONALIZATION OF INDICATORS .50 -- 4 ANALYSIS OF CANCER REGISTRY AND OTHER AVAILABLE DATA 51 -- 4.1 THE STUDY DATABASE - A LINKAGE BETWEEN THE BELGIAN CANCER REGISTRY AND ADMINISTRATIVE DATABASES 51 -- 4.2 THE STUDY COHORT – WOMEN DIAGNOSED IN 2014 - 2018 WITH DCIS OR IBC 51 -- 4.3 DEFINING THE TREATMENT SCHEME OF THE PATIENT 52 -- 4.4 ASSIGNMENT OF EACH PATIENT TO ONE CENTRE .52 -- 4.4.1 Introduction .52 -- 4.4.2 Campus or hospital level 52 -- 4.4.3 Missing campus identification data in the MZG – RHM database 53 -- 4.4.4 Changes during the study period .53 -- 4.4.5 Assignment algorithms 54 -- 4.5 DEFINING THE CAMPUS/HOSPITAL VOLUME 54 -- 4.6 CASE-MIX ADJUSTMENT .54 -- 4.7 STATISTICAL ANALYSES .55 -- 4.7.1 Visualisation of centre variability 55 -- 4.7.2 Estimation of observed and relative survival .56 -- 4.7.3 Modelling observed survival 56 -- 4.7.4 Modelling relative survival 57 -- 4.7.5 Association between campus recognition status/centre volume with processes of care and observed survival 57 -- 4.7.6 Association between campus recognition status/centre volume and relative survival .57 -- 4.7.7 Interpretation of p-values and confidence intervals 57 -- 4.7.8 Statistical software 57 -- 4.8 PRE-VALIDATION OF AVAILABLE DATA AND SOME METHODOLOGICAL ISSUES IN TEN HOSPITALS 58 -- 4.8.1 Objectives and methodology 58 -- 4.8.2 Results 59 -- 4.8.3 Impact of the pre-validation on the methodology and/or interpretation of results 59 -- 4.9 VALIDATION OF THE PROCESS INDICATORS IN ALL BELGIAN HOSPITALS 60 -- 4.9.1 Objectives and methodology 60 -- 4.9.2 Results 61 -- 4.9.3 Impact of the validation study on the methodology and/or interpretation of results 61 -- 4.10 STRENGTHS AND LIMITATIONS OF THE STUDY DATABASE .62 -- 4.10.1 Valuable information not available in the consulted databases 62 -- 4.10.2 Limitations due to invoicing rules .63 -- 4.10.3 Limitations due to the vague description of nomenclature codes 64 -- 4.10.4 Limitations due to unclear or limited validity of some data .64 -- 4.10.5 Treatment performed within the framework of clinical trials 65 -- 5 CHARACTERISTICS OF THE STUDY COHORT .65 -- 5.1 BASELINE DEMOGRAPHICS AND TUMOUR CHARACTERISTICS 65 -- 5.1.1 Patient characteristics 65 -- 5.1.2 Tumour characteristics 67 -- 5.2 MAIN DIAGNOSTIC AND STAGING PROCEDURES .67 -- 5.3 MAIN THERAPEUTIC PROCEDURES 68 -- 5.4 OBSERVED AND RELATIVE SURVIVAL .69 -- 5.4.1 Patients diagnosed with IBC in 2014 - 2018 69 -- 5.4.2 Patients diagnosed with non-metastatic IBC in 2014 - 2018, who had surgery 73 -- 6 ASSOCIATION BETWEEN THE RECOGNITION STATUS/VOLUME OF A CAMPUS AND SURVIVAL .75 -- 6.1 INTRODUCTION .75 -- 6.2 DISTRIBUTION OF BC CARE IN 2014 - 2018 75 -- 6.3 UNADJUSTED ASSOCIATION BETWEEN THE RECOGNITION STATUS AND VOLUME OF A CAMPUS, AND OBSERVED SURVIVAL SINCE DIAGNOSIS OF IBC .76 -- 6.4 ADJUSTED ASSOCIATION BETWEEN THE RECOGNITION STATUS AND VOLUME OF A CAMPUS, AND OBSERVED SURVIVAL SINCE DIAGNOSIS 78 -- 6.5 UNADJUSTED ASSOCIATION BETWEEN THE RECOGNITION STATUS AND VOLUME OF A CAMPUS, AND RELATIVE SURVIVAL SINCE DIAGNOSIS 79 -- 6.6 ADJUSTED ASSOCIATION BETWEEN THE RECOGNITION STATUS AND VOLUME OF A CAMPUS, AND RELATIVE SURVIVAL SINCE DIAGNOSIS 79 -- 6.7 ASSOCIATION BETWEEN HOSPITAL VOLUME AND OBSERVED SURVIVAL SINCE DIAGNOSIS IN THE COMPARISON COHORT (2009 - 2013) 80 -- 7 ASSOCIATION BETWEEN THE RECOGNITION STATUS/VOLUME OF A CAMPUS/HOSPITAL AND PROCESSES & OTHER OUTCOMES OF CARE .81 -- 7.1 DIAGNOSIS & STAGING 82 -- 7.1.1 Mammography and sonography in patients with IBC 82 -- 7.1.2 Assessment of histology and/or cytology before treatment 84 -- 7.1.3 Assessment of receptor status before any systemic treatment 85 -- 7.1.4 Multidisciplinary team (MDT) meeting 88 -- 7.1.5 TNM stage reporting to the BCR 91 -- 7.2 TIME TO TREATMENT 95 -- 7.3 SURGERY 97 -- 7.3.1 No axillary clearance as first axillary surgery in patients with DCIS 97 -- 7.3.2 Sentinel lymph-node biopsy (SLNB) only, in patients with invasive pN0 BC .99 -- 7.3.3 Just one breast surgery .101 -- 7.4 POST-OPERATIVE RADIOTHERAPY IN WOMEN WITH IBC 106 -- 7.5 SYSTEMIC TREATMENT 108 -- 7.5.1 Adjuvant chemotherapy and/or endocrine therapy in patients <70 years with M0 IBC .109 -- 7.5.2 Adjuvant systemic therapy in patients <70 years with M1 IBC 111 -- 8 DISCUSSION .112 -- APPENDICES 117 -- APPENDIX 1. THE EUROPEAN PARLIAMENT RESOLUTION 2002 – CRITERIA FOR CERTIFIED BREAST CENTRES 117 -- APPENDIX 2. ROYAL DECREE OF 26 APRIL 2007, DEFINING THE RECOGNITION CRITERIA FOR BREAST CLINICS 118 -- APPENDIX 3. CARE PROGRAMME FOR BASIC ONCOLOGICAL CARE AND ONCOLOGY CARE PROGRAMME 121 -- APPENDIX 4. ROYAL DECREE OF 2013 - ADAPTATIONS COMPARED TO THE ROYAL DECREE OF 2007 121 -- APPENDIX 5. DISTRIBUTION OF COORDINATING AND SATELLITE BREAST CLINICS OVER THE HOSPITAL NETWORKS .124 -- APPENDIX 6. SELECTION OF QUALITY INDICATORS 127 -- APPENDIX 7. DEFINITION OF BREAST CANCER .133 -- APPENDIX 8. ANALYSIS OF CANCER REGISTRY AND OTHER AVAILABLE DATA .133 -- APPENDIX 8.1. HEALTH INSURANCE DATA (IMA – AIM DATA) 133 -- APPENDIX 8.2. HOSPITAL DISCHARGE DATA - MZG – RHM DATA .164 -- APPENDIX 8.3. IDENTIFICATION OF THE STUDY COHORT IN THE BELGIAN CANCER REGISTRY DATABASE .165 -- APPENDIX 8.4. ASSIGNMENT OF EACH PATIENT TO ONE CENTRE – ASSIGNMENT ALGORITHMS 166 -- APPENDIX 9. PRE-VALIDATION STUDY .170 -- APPENDIX 9.1. LIST OF PARTICIPATING HOSPITALS 170 -- APPENDIX 9.2. INFORMATION PROVIDED TO THE HOSPITALS FOR EACH ASSIGNED PATIENT AND CHECKS ASKED TO BE DONE 170 -- APPENDIX 9.3. RESULTS .171 -- APPENDIX 10. VALIDATION STUDY 180 -- APPENDIX 10.1. VALIDATION OF PROCESS INDICATOR RESULTS 181 -- APPENDIX 10.2. VALIDATION OF VOLUME AND CENTRE ALLOCATION .185 -- APPENDIX 11. DESCRIPTION OF THE STUDY COHORT .186 -- APPENDIX 11.1. PATIENT CHARACTERISTICS .186 -- APPENDIX 11.2. TUMOUR CHARACTERISTICS .190 -- APPENDIX 11.3. MAIN DIAGNOSTIC AND STAGING PROCEDURES 202 -- APPENDIX 11.4. MAIN THERAPEUTIC PROCEDURES 208 -- APPENDIX 11.5. REFERRAL BETWEEN HOSPITALS .229 -- APPENDIX 11.6. OBSERVED AND RELATIVE SURVIVAL 231 -- APPENDIX 12. ASSOCIATION BETWEEN THE RECOGNITION STATUS/VOLUME OF A HOSPITAL CAMPUS AND SURVIVAL 248 -- APPENDIX 12.1. DOCUMENTATION SHEET .248 -- APPENDIX 12.2. DISTRIBUTION OF BC CARE IN 2014 - 2018 250 -- APPENDIX 12.3. UNADJUSTED ASSOCIATION BETWEEN RECOGNITION STATUS AND CAMPUS VOLUME, AND 1-, 3- AND 5-YEAR OBSERVED SURVIVAL SINCE DIAGNOSIS .253 -- APPENDIX 12.4. ADJUSTED ASSOCIATION BETWEEN RECOGNITION STATUS AND CAMPUS VOLUME, AND 1-, 3- AND 5-YEAR OBSERVED SURVIVAL SINCE DIAGNOSIS .256 -- APPENDIX 12.5. UNADJUSTED ASSOCIATION BETWEEN THE RECOGNITION STATUS AND VOLUME OF A CAMPUS, AND RELATIVE SURVIVAL SINCE DIAGNOSIS .257 -- APPENDIX 12.6. ASSOCIATION BETWEEN HOSPITAL VOLUME AND OBSERVED SURVIVAL SINCE DIAGNOSIS IN THE COMPARISON COHORT (2009 - 2013) 261 -- APPENDIX 13. MAMMOGRAPHY AND SONOGRAPHY .264 -- APPENDIX 13.1. DOCUMENTATION SHEET .264 -- APPENDIX 13.2. FLOWCHART 267 -- APPENDIX 13.3. RESULTS 268 -- APPENDIX 14. ASSESSMENT OF HISTOLOGY AND/OR CYTOLOGY BEFORE TREATMENT .278 -- APPENDIX 14.1. DOCUMENTATION SHEET .278 -- APPENDIX 14.2. FLOWCHART 280 -- APPENDIX 14.3. RESULTS 281 -- APPENDIX 15. ASSESSMENT OF RECEPTOR STATUS BEFORE ANY SYSTEMIC TREATMENT .286 -- APPENDIX 15.1. DOCUMENTATION SHEET .286 -- APPENDIX 15.2. FLOWCHART 288 -- APPENDIX 15.3. RESULTS 289 -- APPENDIX 16. MULTIDISCIPLINARY TEAM (MDT) MEETING 294 -- APPENDIX 16.1. DOCUMENTATION SHEET .294 -- APPENDIX 16.2. FLOWCHARTS 296 -- APPENDIX 16.3. RESULTS 298 -- APPENDIX 17. TNM STAGE REPORTING TO THE BCR 304 -- APPENDIX 17.1. DOCUMENTATION SHEET .304 -- APPENDIX 17.2. FLOWCHARTS 306 -- APPENDIX 17.3. RESULTS 308 -- APPENDIX 18. TIME TO TREATMENT 320 -- APPENDIX 18.1. DOCUMENTATION SHEET .320 -- APPENDIX 18.2. FLOWCHART 322 -- APPENDIX 18.3. RESULTS 323 -- APPENDIX 19. NO AXILLARY CLEARANCE IN PATIENTS WITH DCIS 333 -- APPENDIX 19.1. DOCUMENTATION SHEET .333 -- APPENDIX 19.2. FLOWCHART 335 -- APPENDIX 19.3. RESULTS 336 -- APPENDIX 20. SENTINEL LYMPH-NODE BIOPSY (SLNB) ONLY IN PATIENTS WITH IBC .341 -- APPENDIX 20.1. DOCUMENTATION SHEET .341 -- APPENDIX 20.2. FLOWCHART 343 -- APPENDIX 20.3. RESULTS 344 -- APPENDIX 21. JUST ONE BREAST SURGERY IN DCIS 350 -- APPENDIX 21.1. DOCUMENTATION SHEET .350 -- APPENDIX 21.2. FLOWCHART 352 -- APPENDIX 21.3. RESULTS 353 -- APPENDIX 22. JUST ONE BREAST SURGERY IN IBC 362 -- APPENDIX 22.1. DOCUMENTATION SHEET .362 -- APPENDIX 22.2. FLOWCHART 364 -- APPENDIX 22.3. RESULTS 365 -- APPENDIX 23. POST-OPERATIVE RADIOTHERAPY IN WOMEN WITH IBC .375 -- APPENDIX 23.1. DOCUMENTATION SHEET .375 -- APPENDIX 23.2. FLOWCHART 377 -- APPENDIX 23.3. RESULTS 378 -- APPENDIX 24. ADJUVANT CHEMOTHERAPY AND/OR ENDOCRINE THERAPY IN PATIENTS <70 YEARS WITH M0 IBC 384 -- APPENDIX 24.1. DOCUMENTATION SHEET .384 -- APPENDIX 24.2. INDICATOR A - ADJUVANT CHEMOTHERAPY IN M0 IBC 386 -- APPENDIX 24.3. INDICATOR B - ADJUVANT ENDOCRINE THERAPY IN M0 IBC .395 -- APPENDIX 25. ADJUVANT SYSTEMIC THERAPY IN PATIENTS <70 YEARS WITH M1 IBC 404 -- APPENDIX 25.1. DOCUMENTATION SHEET .404 -- APPENDIX 25.2. FLOWCHART 406 -- APPENDIX 25.3. RESULTS 407 -- REFERENCES 411 Link for e-copy: http://doi.org/10.57598/R365C Format of e-copy: PDF (12 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4901 Syndrome de Fatigue Chronique: / Sabine Stordeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
Syndrome de Fatigue Chronique: : diagnostic, traitement et organisation des soins [printed text] / Sabine Stordeur, Author ; Nancy Thiry, Author ; Marijke Eyssen , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2008 . - ix, 125 p. : ill. ; 30 cm.. - (KCE Reports B. Health Services Research (HSR); 88B) .
ISSN : D/2008/10.273/59 : 0 €
Etude nr 2007-32-04
Languages : English (eng) French (fre)
Descriptors: Classification
WB 146 Asthenia. Cachexia. Fatigue
Indexation
2007-32-04 ; Developed Countries ; Diagnosis ; Evidence-Based Medicine ; Fatigue Syndrome, Chronic ; Health Services Research ; R88Link for e-copy: https://doi.org/10.57598/R88B Format of e-copy: .PDF (1.19 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1539 Copies(0)
Status No copy Le syndrome post-soins intensifs (PICS) / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2020)
Le syndrome post-soins intensifs (PICS) : Synthèse [printed text] / Germaine Hanquet, Author ; Nadia Benahmed, Author ; Diego Castanares-Zapatero , Author ; Marie Dauvrin , Author ; Anja Desomer, Author ; Jef Adriaenssens , Author ; Karin Rondia, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2020 . - 27 p. : ill., ; A4. - (COVID-19 – KCE CONTRIBUTIONS, ISSN 2684-5830) .
ISSN : D/2020/10.273/12 : € 0,00
Languages : French (fre)
Descriptors: Classification
WX 218 Intensive care units. Critical care (General)
Indexation
Coronavirus Infections ; Physician's Practice Patterns ; Postintensive care syndrome [Supplementary Concept]Abstract: L’épidémie de COVID braque actuellement tous les projecteurs sur les soins intensifs et les chiffres de mortalité. Mais une fois revenus chez eux, les patients qui auront traversé cette épreuve ne seront pas toujours au bout de leurs peines. Et leurs médecins généralistes non plus. En effet, on doit aussi envisager la possibilité d’une vague de « syndromes post-soins intensifs ». Assez mal connu du grand public, mais aussi du monde de la santé, ce syndrome comporte à la fois des manifestations physiques, psychologiques et cognitives. Il peut apparaître chez plus de la moitié des personnes hospitalisées en soins intensifs pour un problème grave (pas seulement en cas de COVID-19). Le Centre fédéral d’Expertise des Soins de santé (KCE) publie aujourd’hui un rapport destiné à attirer l’attention des médecins généralistes sur ce problème qui passe souvent au second plan une fois la vie sauvée. Et il leur propose quelques tests pratiques pour en détecter les premiers signes le plus tôt possible. Contents note: TABLE DES MATIÈRES 1 -- 1. INTRODUCTION 3 -- 1.1. QU’EST-CE QUE LE PICS ? 3 -- 1.2. POURQUOI CETTE ÉTUDE ? 3 -- 1.3. CONTENU DE CE RAPPORT 4 -- 1.4. LIMITATIONS 4 -- 2. LE VÉCU DES PATIENTS EN SOINS INTENSIFS 5 -- 2.1. PROXIMITÉ DE LA MORT 5 -- 2.2. TRANSFORMATION DES PERCEPTIONS 5 -- 2.3. TRANSFORMATION DU CORPS 5 -- 2.4. PERTE DE LA PERCEPTION DU TEMPS 6 -- 2.5. COMMUNICATION AVEC LES PROFESSIONNELS DE LA SANTÉ 6 -- 2.6. IMPORTANCE DE LA FAMILLE ET DES PROCHES 6 -- 3. LES SYMPTÔMES PHYSIQUES 7 -- 3.1. FACTEURS DE RISQUE CONNUS 7 -- 4. LES SYMPTÔMES PSYCHOLOGIQUES ET LE STRESS POST-TRAUMATIQUE 8 -- 4.1. ANXIÉTÉ ET DÉPRESSION 8 -- 4.2. SYMPTÔMES ET SYNDROME DE STRESS POST-TRAUMATIQUE 9 -- 4.3. FACTEURS DE RISQUE CONNUS 9 -- 5. LES SYMPTÔMES COGNITIFS 10 -- 5.1. FACTEURS DE RISQUE CONNUS 10 -- 6. LES SYMPTÔMES PSYCHOLOGIQUES CHEZ LES PROCHES (PICS-F) 11 -- 6.1. FACTEURS DE RISQUE CONNUS 11 -- 7. LE BESOIN D’INFORMATION 12 -- 7.1. QUE S’EST-IL PASSÉ ? 12 -- 7.2. QUE VA-T-IL SE PASSER ? 12 -- 7.3. ET…QUE SAVENT CEUX QUI ME SOIGNENT ? 13 -- 8. OUTILS DE DÉTECTION 14 -- 8.1. ÉVALUATION DE LA FONCTION PHYSIQUE 15 -- 8.2. DÉTECTION DES SYMPTÔMES PSYCHOLOGIQUES 16 -- 8.3. DÉTECTION DES SYMPTÔMES COGNITIFS 17 -- 9. INTERVENTIONS POSSIBLES 18 -- 9.1. REVALIDATION NEUROMUSCULAIRE 18 -- 9.1.1. Nomenclature M (kinésithérapie) 18 -- 9.1.2. Nomenclature K (médecine physique) 18 -- 9.2. REVALIDATION COGNITIVE 19 -- 9.3. INTERVENTIONS PORTANT SUR LA SANTÉ MENTALE 20 -- 9.4. CONSULTATIONS POST-SOINS INTENSIFS 22 -- 9.5. JOURNAUX DE BORD 23 -- 9.6. GROUPES D’ENTRAIDE 24 -- 9.7. INTERVENTIONS POUR LE PICS-F 25 -- 9.8. RETOUR AU TRAVAIL 25 -- 10. CONCLUSION 26 Link for e-copy: https://kce.fgov.be/sites/default/files/atoms/files/Synthese_PICS_FR_.pdf Format of e-copy: PDF (0,62 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4679 Synthèse du rapport ‘Etat des lieux de l’ostéopathie et de la chiropraxie en Belgique’ / Tom De Gendt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkSystematic review of healthcare use and needs of prisoners / Michal Witkowski / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2017)
PermalinkLe système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkLe système de santé belge en 2010 / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkSystèmes de financement des medicaments hospitaliers / Nathalie Swartenbroekx / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2004)
PermalinkLes systèmes de remboursement des médicaments / Maïté le Polain / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkTechniques innovantes en radiothérapie / Frank Hulstaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
PermalinkTelemonitoring bij patienten met COVID-19 / Justien Cornelis / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2022)
PermalinkTélémonitoring des patients COVID-19 / Justien Cornelis / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2022)
PermalinkTen years of multidisciplinary teams meetings in oncology / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
Permalink
GRID: https://grid.ac/institutes/grid.414403.6
ISN: http://isni.org/isni/0000000406298370